Evidence map›Paper›PMID 27071676›Full record

ArticleScientific reports2016

Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions.

Mariano Di Trapani, Giulio Bassi, Martina Midolo, Alessandro Gatti, Paul Takam Kamga, Adriana Cassaro, Roberta Carusone, Annalisa Adamo, Mauro Krampera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers.

0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

185 citing papers in PubMed, 282 citations in OpenAlex.

  1. Biology and Therapeutic Potential of Exosomes, Targeted Drug Delivery.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

125 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mariano Di TrapaniStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Giulio BassiStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Martina MidoloStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Alessandro GattiStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Paul Takam KamgaStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Adriana CassaroStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Roberta CarusoneStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Annalisa AdamoStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
Mauro KramperaStem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are multipotent cells, immunomodulatory stem cells that are currently used for regenerative medicine and treatment of a number of inflammatory diseases, thanks to their ability to significantly influence tissue microenvironments through the secretion of large variety of soluble factors. Recently, several groups have reported the presence of extracellular vesicles (EVs) within MSC secretoma, showing their beneficial effect in different animal models of disease. Here, we used a standardized methodological approach to dissect the immunomodulatory effects exerted by MSC-derived EVs on unfractionated peripheral blood mononuclear cells and purified T, B and NK cells. We describe here for the first time: i. direct correlation between the degree of EV-mediated immunosuppression and EV uptake by immune effector cells, a phenomenon further amplified following MSC priming with inflammatory cytokines; ii. induction in resting MSCs of immunosuppressive properties towards T cell proliferation through EVs obtained from primed MSCs, without any direct inhibitory effect towards T cell division. Our conclusion is that the use of reproducible and validated assays is not only useful to characterize the mechanisms of action of MSC-derived EVs, but is also capable of justifying EV potential use as alternative cell-free therapy for the treatment of human inflammatory diseases.

Indexed as

B-LymphocytesCells, CulturedCross-PrimingCytokinesExtracellular VesiclesHumansKiller Cells, NaturalMesenchymal Stem CellsT-LymphocytesCytokines

Identifiers

PMID27071676
PMCPMC4829861
OpenAlexW2340631986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.